Antipsychotic‐induced extrapyramidal adverse effects are well recognized in the context of
first‐generation antipsychotic drugs. However, the introduction of second‐generation …

The introduction of atypical antipsychotics (AAPs) since the discovery of its prototypical drug
clozapine has been a revolutionary pharmacological step for treating psychotic patients as …

The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …

Objective: Tardive dyskinesia is a persistent movement disorder induced by dopamine
receptor blockers, including antipsychotics. Valbenazine (NBI-98854) is a novel, highly …

Tardive dyskinesia (TD) risk with D2/serotonin receptor antagonists or D2 receptor partial
agonists (second‐generation antipsychotics, SGAs) is considered significantly lower than …

Background Tardive dyskinesia results from exposure to dopamine receptor antagonists,
such as typical and atypical antipsychotics. If clinically appropriate, clinicians often manage …

Objective: To determine the efficacy and safety of deutetrabenazine as a treatment for
tardive dyskinesia (TD). Methods: One hundred seventeen patients with moderate to severe …

Aims: We aim to identify the prevalence and management strategies of nine clinically
important categories of antipsychotic adverse effects, namely: extrapyramidal symptoms; …

Introduction Drug-induced parkinsonism (DIP) and tardive dyskinesia (TD) are stigmatizing
movement disorders associated with exposure to dopamine receptor blocking agents such …

Page 1 Joanna Moncrieff Author of The Myth of º the Chemical Cure THE CBITTEREST The
Troubling Story of Antipsychotic Drugs * Page 2 The Bitterest Pills Page 3 Also by Joanna …